Valuation: Clene Inc.

Market Cap 55.89M 48.74M 46.02M 41.79M 78.29M 5.36B 78.62M 551M 213M 2.73B 210M 205M 8.77B P/E 2026 *
-1.69x
P/E 2027 * -2.55x
Enterprise Value 51.29M 44.73M 42.23M 38.35M 71.85M 4.92B 72.15M 506M 195M 2.5B 193M 188M 8.05B EV / Sales 2026 *
206x
EV / Sales 2027 * 2.48x
Free-Float
84.66%
Yield 2026 *
-
Yield 2027 * -
1 day+4.82%
1 week+21.85%
Current month+1.64%
1 month+3.82%
3 months-27.62%
6 months-25.89%
Current year-25.89%
1 week 3.25
Extreme 3.25
4.44
1 month 3.25
Extreme 3.25
4.8
Current year 3.25
Extreme 3.25
8.67
1 year 3.25
Extreme 3.25
13.5
3 years 2.28
Extreme 2.2801
13.5
5 years 2.28
Extreme 2.2801
159.59
10 years 2.28
Extreme 2.2801
356.4
Manager TitleAgeSince
Chief Executive Officer 59 01/04/2013
Chief Tech/Sci/R&D Officer 67 01/01/2013
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 65 01/11/2015
Director/Board Member 53 01/09/2019
Director/Board Member 49 01/12/2020
Date Insider Type Main position Quantity % Market Cap. Importance
8/13/26 A Free

Founder

3,514 0.0275%
8/13/26 A Free

Director

3,514 0.0275%
8/13/26 A Free

Director

3,674 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
+4.82%+21.85%-31.92%-55.47% 55.89M
-0.31%+5.79%+47.13%+99.00% 70.88B
+0.39%+2.06%+39.38%+78.27% 62.49B
-3.21%-7.27%-17.10%+356.10% 26.21B
+0.50%+7.13%+33.27%+16.01% 26.34B
-2.64%-0.69%-0.17%-13.01% 24.13B
+0.71%+8.03%+25.03%-12.74% 20.72B
-1.26%-7.81%+156.15%+320.43% 15.36B
-0.22%+3.99%+45.54%+172.46% 14.46B
+0.73%+1.71%-5.51%+849.47% 14.25B
Average -0.05%+3.67%+29.18%+181.05% 27.49B
Weighted average by Cap. -0.47%+1.44%+35.36%+147.70%

Financials

2026 *2027 *
Net sales 249K 217K 205K 186K 349K 23.93M 351K 2.46M 949K 12.17M 937K 916K 39.15M 23.27M 20.29M 19.16M 17.4M 32.59M 2.23B 32.73M 229M 88.55M 1.14B 87.4M 85.46M 3.65B
Net income -34.49M -30.07M -28.4M -25.79M -48.31M -3.31B -48.51M -340M -131M -1.68B -130M -127M -5.41B -31M -27.03M -25.52M -23.18M -43.42M -2.97B -43.61M -306M -118M -1.51B -116M -114M -4.87B
Net Debt -4.6M -4.01M -3.79M -3.44M -6.44M -441M -6.47M -45.37M -17.51M -224M -17.28M -16.9M -722M 1.8M 1.57M 1.48M 1.35M 2.52M 173M 2.53M 17.75M 6.85M 87.81M 6.76M 6.61M 283M
Logo Clene Inc.
Clene Inc. is a clinical-stage pharmaceutical company, which is engaged in discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.
Employees
-
Date Price Change Volume
18/09/26 $4.350 +4.82% 191,432
17/09/26 $4.150 +7.51% 138,806
16/09/26 $3.860 -3.98% 256,176
15/09/26 $4.020 +22.56% 479,089
14/09/26 $3.280 -8.12% 140,858
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.350USD
Average target price
32.20USD
Spread / Average Target
+640.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CLNN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!